TY - JOUR
T1 - Randomized trial of the effect of four second-generation antipsychotics and one first-generation antipsychotic on cigarette smoking, alcohol, and drug use in chronic schizophrenia
AU - Mohamed, Somaia
AU - Rosenheck, Robert A.
AU - Lin, Haiqun
AU - Swartz, Marvin
AU - McEvoy, Joseph Patrick
AU - Stroup, Scott
N1 - Publisher Copyright:
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2015/7/1
Y1 - 2015/7/1
N2 - No large-scale randomized trial has compared the effect of different second-generation antipsychotic drugs and any first-generation drug on alcohol, drug and nicotine use in patients with schizophrenia. The Clinical Antipsychotic Trial of Intervention Effectiveness study randomly assigned 1432 patients formally diagnosed with schizophrenia to four second-generation antipsychotic drugs (olanzapine, risperidone quetiapine, and ziprasidone) and one first-generation antipsychotic (perphenazine) and followed them for up to 18 months. Secondary outcome data documented cigarettes smoked in the past week and alcohol and drug use severity ratings. At baseline, 61% of patients smoked, 35% used alcohol, and 23% used illicit drugs. Although there were significant effects of time showing reduction in substance use over the 18 months (all p < 0.0001), this study found no evidence that any antipsychotic was robustly superior to any other in a secondary analysis of data on substance use outcomes from a large 18-month randomized schizophrenia trial.
AB - No large-scale randomized trial has compared the effect of different second-generation antipsychotic drugs and any first-generation drug on alcohol, drug and nicotine use in patients with schizophrenia. The Clinical Antipsychotic Trial of Intervention Effectiveness study randomly assigned 1432 patients formally diagnosed with schizophrenia to four second-generation antipsychotic drugs (olanzapine, risperidone quetiapine, and ziprasidone) and one first-generation antipsychotic (perphenazine) and followed them for up to 18 months. Secondary outcome data documented cigarettes smoked in the past week and alcohol and drug use severity ratings. At baseline, 61% of patients smoked, 35% used alcohol, and 23% used illicit drugs. Although there were significant effects of time showing reduction in substance use over the 18 months (all p < 0.0001), this study found no evidence that any antipsychotic was robustly superior to any other in a secondary analysis of data on substance use outcomes from a large 18-month randomized schizophrenia trial.
KW - Alcohol dependence
KW - Drug dependence
KW - Schizophrenia
KW - Second-generation antipsychotics
KW - Smoking
UR - http://www.scopus.com/inward/record.url?scp=84941061004&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941061004&partnerID=8YFLogxK
U2 - 10.1097/NMD.0000000000000317
DO - 10.1097/NMD.0000000000000317
M3 - Article
C2 - 26075840
AN - SCOPUS:84941061004
SN - 0022-3018
VL - 203
SP - 486
EP - 492
JO - Journal of Nervous and Mental Disease
JF - Journal of Nervous and Mental Disease
IS - 7
ER -